Cardiomyocyte microvesicles: proinflammatory mediators after myocardial ischemia?


Journal

Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 17 6 2020
medline: 5 8 2021
entrez: 16 6 2020
Statut: ppublish

Résumé

Myocardial infarction is a frequent complication of cardiovascular disease leading to high morbidity and mortality worldwide. Elevated C-reactive protein (CRP) levels after myocardial infarction are associated with heart failure and poor prognosis. Cardiomyocyte microvesicles (CMV) are released during hypoxic conditions and can act as mediators of intercellular communication. MicroRNA (miRNA) are short non-coding RNA which can alter cellular mRNA-translation. Microvesicles (MV) have been shown to contain distinct patterns of miRNA from their parent cells which can affect protein expression in target cells. We hypothesized that miRNA containing CMV mediate hepatic CRP expression after cardiomyocyte hypoxia. H9c2-cells were cultured and murine cardiomyocytes were isolated from whole murine hearts. H9c2- and murine cardiomyocytes were exposed to hypoxic conditions using a hypoxia chamber. Microvesicles were isolated by differential centrifugation and analysed by flow cytometry. Next-generation-sequencing was performed to determine the miRNA-expression profile in H9c2 CMV compared to their parent cells. Microvesicles were incubated with a co-culture model of the liver consisting of THP-1 macrophages and HepG2 cells. IL-6 and CRP expression in the co-culture was assessed by qPCR and ELISA. CMV contain a distinct pattern of miRNA compared to their parent cells including many inflammation-related miRNA. CMV induced IL-6 expression in THP-1 macrophages alone and CRP expression in the hepatic co-culture model. MV from hypoxic cardiomyocytes can mediate CRP expression in a hepatic co-culture model. Further studies will have to show whether these effects are reproducible in-vivo.

Identifiants

pubmed: 32537679
doi: 10.1007/s11239-020-02156-x
pii: 10.1007/s11239-020-02156-x
pmc: PMC8443479
doi:

Substances chimiques

Interleukin-6 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

533-542

Commentaires et corrections

Type : ErratumIn

Références

Circ Res. 2018 Jun 22;123(1):100-106
pubmed: 29592957
Front Physiol. 2019 Aug 20;10:1049
pubmed: 31481897
Mol Immunol. 2001 Aug;38(2-3):189-97
pubmed: 11532280
J Extracell Vesicles. 2014 Mar 26;3:
pubmed: 24683445
J Thromb Haemost. 2010 Dec;8(12):2810-9
pubmed: 21029362
J Mol Cell Cardiol. 2012 Dec;53(6):848-57
pubmed: 23085511
Cell Physiol Biochem. 2017;42(6):2207-2219
pubmed: 28817807
J Biol Chem. 2004 Nov 19;279(47):48487-90
pubmed: 15337754
J Mol Cell Cardiol. 2019 Apr;129:281-292
pubmed: 30878395
Toxicol In Vitro. 2006 Dec;20(8):1488-99
pubmed: 16782301
Structure. 1999 Feb 15;7(2):169-77
pubmed: 10368284
J Am Coll Cardiol. 2006 Mar 7;47(5):962-8
pubmed: 16516078
Clin Cancer Res. 2008 Mar 1;14(5):1340-8
pubmed: 18316553
Sci Rep. 2017 Nov 21;7(1):15974
pubmed: 29162889
PLoS One. 2017 Jun 29;12(6):e0179850
pubmed: 28662100
Inflamm Res. 2014 Jul;63(7):539-47
pubmed: 24599284
Am J Med. 2007 Jul;120(7):616-22
pubmed: 17602936
J Mol Cell Cardiol. 2014 Mar;68:75-8
pubmed: 24440457
Circulation. 2019 Mar 5;139(10):e56-e528
pubmed: 30700139
Methods Mol Biol. 2007;357:271-96
pubmed: 17172694
J Genet Genomics. 2011 Mar 20;38(3):95-109
pubmed: 21477781
Eur Respir J. 2011 Jun;37(6):1494-502
pubmed: 21148223
Haematologica. 2009 Jun;94(6):773-80
pubmed: 19454498
Am J Transl Res. 2018 Dec 15;10(12):4350-4366
pubmed: 30662677
Cardiovasc Res. 2012 Oct 1;96(1):64-72
pubmed: 22798388
Nat Cell Biol. 2007 Jun;9(6):654-9
pubmed: 17486113
J Mol Cell Cardiol. 1992 Jun;24(6):579-84
pubmed: 1518075
Nat Protoc. 2006;1(3):1458-61
pubmed: 17406435
Scand Cardiovasc J. 2007 Jun;41(3):149-54
pubmed: 17487763
Cardiology. 2015;132(4):233-41
pubmed: 26337652
J Am Heart Assoc. 2017 Feb 27;6(3):
pubmed: 28242633
Perspect Clin Res. 2016 Apr-Jun;7(2):68-74
pubmed: 27141472
J Lab Clin Med. 1992 May;119(5):574-9
pubmed: 1583414
Circulation. 2014 Jul 1;130(1):35-50
pubmed: 24982116
J Am Coll Cardiol. 2018 Jul 10;72(2):199-201
pubmed: 29976294
PLoS One. 2012;7(4):e34653
pubmed: 22506041
Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H3052-6
pubmed: 17307989
J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):317-22
pubmed: 17662623
Cardiovasc Res. 2012 Mar 15;93(4):633-44
pubmed: 22258631
Am J Med. 2003 Dec 15;115(9):695-701
pubmed: 14693321
Sci Rep. 2016 Oct 27;6:35928
pubmed: 27786276
J Cell Mol Med. 2015 Sep;19(9):2153-61
pubmed: 25824442
Crit Care. 2015 Feb 26;19:58
pubmed: 25886988
Cardiovasc Res. 2020 May 1;116(6):1113-1124
pubmed: 31782762

Auteurs

Patrick Malcolm Siegel (PM)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany. patrick.siegel@universitaets-herzzentrum.de.
Baker Heart & Diabetes Institute, Atherothrombosis & Vascular Biology Laboratory, Melbourne, Australia. patrick.siegel@universitaets-herzzentrum.de.

Judith Schmich (J)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.
Baker Heart & Diabetes Institute, Atherothrombosis & Vascular Biology Laboratory, Melbourne, Australia.

Georg Barinov (G)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.

István Bojti (I)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.

Christopher Vedecnik (C)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.

Novita Riani Simanjuntak (NR)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.

Christoph Bode (C)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.

Martin Moser (M)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.

Karlheinz Peter (K)

Baker Heart & Diabetes Institute, Atherothrombosis & Vascular Biology Laboratory, Melbourne, Australia.
Faculty for Medicine & Nursing, Monash University, Melbourne, Australia.

Philipp Diehl (P)

Cardiology and Angiology I, Heart Center Freiburg University, Medical Faculty, University of Freiburg, 79106, Freiburg im Breisgau, Germany.
Baker Heart & Diabetes Institute, Atherothrombosis & Vascular Biology Laboratory, Melbourne, Australia.
Faculty for Medicine & Nursing, Monash University, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH